Author Correction: Serum GFAP as a biomarker for disease severity in multiple sclerosis

Correction to: Scientific Reports 10.1038/s41598-018-33158-8, published online 04 October 2018

In Figure 5, the values for the PMS subgroup are duplicated in both 5a and 5b. The correct Figure 5 appears below as Figure 1.

Figure 1.

Quotient of glial fibrillary acidic protein (GFAP) and neurofilaments light (NfL) in cerebrospinal fluid (CSF) and serum in progressive multiple sclerosis patients (PMS) compared to relapsing-remitting multiple sclerosis (RRMS). n.s.: not significant.